4.5 Article Proceedings Paper

In vitro efficacy of bumped kinase inhibitors against Besnoitia besnoiti tachyzoites

Journal

INTERNATIONAL JOURNAL FOR PARASITOLOGY
Volume 47, Issue 12, Pages 811-821

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.ijpara.2017.08.005

Keywords

Besnoitia besnoiti; Chemotherapy; Bumped kinase inhibitors; CDPK1; In vitro assay

Categories

Funding

  1. Spanish Ministry of Economy and Competitiveness [AGL2013-04442]
  2. Community of Madrid, Spain (PLATESA-CM) [S2013/ABI-2906]
  3. Swiss National Science Foundation [310030_165782, CRSII3_160702]
  4. National Institute of Allergy and Infectious Diseases, USA
  5. National Institute of Child Health and Human Development of the National Institutes of Health, USA [R01AI089441, R01AI111341, R01HD080670]
  6. United States Department of Agriculture National Institute of Food and Agriculture [2014-06183]
  7. Spanish Ministry of Education, Culture and Sports [FPU13/05481]
  8. Swiss National Science Foundation (SNF) [CRSII3_160702] Funding Source: Swiss National Science Foundation (SNF)

Ask authors/readers for more resources

Besnoitia besnoiti is an apicomplexan parasite responsible for bovine besnoitiosis, a chronic and debilitating disease that causes systemic and skin manifestations and sterility in bulls. Neither treatments nor vaccines are currently available. In the search for therapeutic candidates, calcium-dependent protein kinases have arisen as promising drug targets in other apicomplexans (e.g. Neospora caninum, Toxoplasma gondii, Plasmodium spp. and Eimeria spp.) and are effectively targeted by bumped kinase inhibitors. In this study, we identified and cloned the gene coding for BbCDPK1. The impact of a library of nine bumped kinase inhibitor analogues on the activity of recombinant BbCDPK1 was assessed by luciferase assay. Afterwards, those were further screened for efficacy against Besnoitiabesnoiti tachyzoites grown in Marc-145 cells. Primary tests at 5 mu M revealed that eight compounds exhibited more than 90% inhibition of invasion and proliferation. The compounds BKI 1294, 1517, 1553 and 1571 were further characterised, and EC99 (1294: 2.38 mu M; 1517: 2.20 mu M; 1553: 3.34 mu M; 1571: 2.78 mu M) were determined by quantitative real-time polymerase chain reaction in 3-day proliferation assays. Exposure of infected cultures with EC99 concentrations of these drugs for up to 48 h was not parasiticidal. The lack of parasiticidal action was confirmed by transmission electron microscopy, which showed that bumped kinase inhibitor treatment interfered with cell cycle regulation and non-disjunction of tachyzoites, resulting in the formation of large multi-nucleated complexes which co-existed with viable parasites within the parasitophorous vacuole. However, it is possible that, in the face of an active immune response, parasite clearance may occur. In summary, bumped kinase inhibitors may be effective drug candidates to control Besnoitiabesnoiti infection. Further in vivo experiments should be planned, as attainment and maintenance of therapeutic blood plasma levels in calves, without toxicity, has been demonstrated for BKIs 1294, 1517 and 1553. (C) 2017 Australian Society for Parasitology. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available